Transcutaneous Occipital Nerve Stimulation as a Migraine Prevention Alternative

Understanding Migraine

Migraine is a prevalent and debilitating condition characterized by severe, pulsating headaches typically affecting one side of the head. These headaches can last from several hours to days and are often accompanied by symptoms such as nausea and sensitivity to light and sound. Some individuals experience “migraine with aura,” where visual disturbances like blind spots or flashing lights precede the headache.

The frequency and severity of migraine attacks vary among individuals, making it a complex condition to manage. According to the Global Burden of Disease Study, migraines rank as the third most common disease and the sixth leading cause of disability worldwide, affecting approximately 14.7% of the global population. Consequently, researching effective migraine prevention methods is crucial.

Common Triggers and Treatment Challenges

Many migraine sufferers identify specific triggers, such as certain foods, hormonal changes, bright lights, or weather fluctuations. While some can avoid these triggers, others may require medication for prevention. Topiramate is currently the first-choice drug, but not all patients tolerate it well, highlighting the need for alternative approaches.

Several nerve stimulation techniques have been explored, though many require surgical implants, which may not be suitable for those with less severe migraines.

Research on Transcutaneous Occipital Nerve Stimulation (tONS)

A team of researchers in Beijing, China, has investigated a non-invasive technique called transcutaneous occipital nerve stimulation (tONS), which involves stimulating the occipital nerve at the back of the head using surface electrodes. Their findings were published in The Journal of Pain.

The study included patients with a minimum one-year history of migraine without aura, who attended the outpatient clinic at the PLA General Hospital Beijing. A total of 128 participants were randomly assigned to one of five groups: three groups receiving tONS at different electrical frequencies, one placebo group receiving non-conducting electrodes, and one group receiving oral topiramate.

The tONS groups underwent daily therapy sessions, where an electrical stimulator connected to self-adhesive electrodes was applied to the back of the head over the occipital nerves. The stimulation lasted for 30 minutes, with intensity adjusted accordingly. The topiramate group started with a daily dose of 25 mg, increasing weekly to a maximum of 50 mg twice daily after four weeks.

Study Findings and Conclusions

All participants maintained headache diaries for four weeks before treatment and during the four-week treatment period, recording migraine frequency, intensity, and duration. Researchers compared the groups to determine the 50% responder rate, defined as a minimum 50% reduction in monthly migraine days from baseline to the treatment period.

Of the 110 patients who completed the study, the 50% responder rate was significantly higher in the tONS and topiramate groups compared to the placebo group. Additionally, headache intensity was notably lower in the treatment groups. There was no significant difference in response among the tONS groups treated at varying frequencies.

The researchers concluded that tONS therapy is a safe and effective new method for preventing migraine headaches and may serve as a promising alternative for those who do not respond well to conventional drug treatments.

Reference

Liu Y, Zhao D, Wang R, et al. Migraine prevention using different frequencies of transcutaneous occipital nerve stimulation: a randomized controlled trial. The Journal of Pain, Vol 18, No. * (August), 2017: pp 1006-1015. (Available online at: www.jpain.org and www.sciencedirect.com)